跳至主要内容
临床试验/JPRN-UMIN000046150
JPRN-UMIN000046150招募中未知

Modulation of the antidepressant response of ketamine by an immunosuppressant and mTORC1 inhibitor, Rapamycin: a prospective study using randomized, double-blind, placebo controlled clinical trial - Modulation of the antidepressant response of ketamine by an immunosuppressant and mTORC1 inhibitor, Rapamycin: a prospective study using randomized, double-blind, placebo controlled clinical trial

CHENG HSIN GENERAL HOSPITA0 个研究点目标入组 80 人开始时间: 2021年11月23日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer).2.Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. 3.Pregnancy and Breastfeeding women.4.Substance abuse in previous 6 months such as cocaine, marijuana, opium, ketamine,PCP (phencyclidine)5.Current use of NMDA receptor antagonist (Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan) 6) Alcohol abuse / dependence within 6 months. 7) Allergy to Ketamine and Rapamycin 8)Those unable to express willingness to participate

研究者

发起方
CHENG HSIN GENERAL HOSPITA

相似试验